Associations of habitual glucosamine use with SARS‐CoV‐2 infection and hospital admission and death with COVID‐19: Evidence from a large population based cohort study

Abstract

The coronavirus disease 2019 pandemic has led to a fundamental number of morbidity and mortality worldwide. Glucosamine was indicated to help prevent and control RNA virus infection preclinically, while its potential therapeutic effects on COVID-19-related outcomes are largely unknown. To assess the association of habitual glucosamine use with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospital admission, and mortality with COVID-19 in a large population based cohort. Participants from UK Biobank were reinvited between June and September 2021 to have SARS-CoV-2 antibody testing. The associations between glucosamine use and the risk of SARS-CoV-2 infection were estimated by logistic regression. Hazard ratios (HRs) and 95% confidence intervals (CIs) for COVID-19-related outcomes were calculated using COX proportional hazards model. Furthermore, we carried out propensity-score matching (PSM) and stratified analyses. At baseline, 42 673 (20.7%) of the 205 704

Uncovering the Effect of SARS-CoV-2 on Liver Metabolism via Genome-Scale Metabolic Modeling for Reprogramming and Therapeutic Strategies

“…Several studies in the literature demonstrated that the supplements used in this study like dopamine, glucosamine, D -xylose, cysteine, ( R )-3-hydroxybutanoate, lovastatin, and simvastatin have the potential to develop therapeutic strategies to fight SARS-CoV-2. − Dopamine is an important neurotransmitter and required for proper functioning of the body including movement, memory, and motivation. Administration of dopamine reduced the viral replication in CaLu-3 human lung epithelial cells and virus-based cytopathic effect in Vero E6 epithelial cells infected with SARS-CoV-2. , Glucosamine is a common dietary supplement that promotes joint health.…”

“…Its administration to infected Calu-3 cells and mice inhibited SARS-CoV-2 replication in vitro and in vivo , respectively . In a large population cohort study, the use of habitual glucosamine was connected with decreased hospitalization and mortality due to COVID-19 . The probable therapeutic use of D -xylose was suggested for the treatment of COVID-19 patients …”

“… 52 In a large population cohort study, the use of habitual glucosamine was connected with decreased hospitalization and mortality due to COVID-19. 53 The probable therapeutic use of D -xylose was suggested for the treatment of COVID-19 patients. 54 N -acetylcysteine is widely used as a health supplement and precursor of cysteine.…”